PATHOLOGIC STAGE IV CUTANEOUS MELANOMA AJCC V8
Clinical trials for PATHOLOGIC STAGE IV CUTANEOUS MELANOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new PATHOLOGIC STAGE IV CUTANEOUS MELANOMA AJCC V8 trials appear
Sign up with your email to follow new studies for PATHOLOGIC STAGE IV CUTANEOUS MELANOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
PET scans may let melanoma patients stop treatment sooner
Disease control OngoingThis study looks at whether doctors can safely stop standard anti-PD-1 immunotherapy early in people with advanced melanoma that cannot be surgically removed. By using PET/CT scans and tumor biopsies as guides, the goal is to reduce treatment side effects and burden without harmi…
Matched conditions: PATHOLOGIC STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 16, 2026 12:52 UTC
-
New hope for brain metastases: targeted radiation may protect memory
Disease control OngoingThis study looks at whether a focused, one-time radiation treatment called stereotactic radiosurgery (SRS) can control melanoma tumors that have spread to more than three spots in the brain while also protecting memory and thinking skills. About 49 adults with advanced melanoma a…
Matched conditions: PATHOLOGIC STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC
-
New combo aims to tame immunotherapy side effects in advanced cancers
Disease control OngoingThis study tests whether adding tocilizumab to standard immunotherapy (ipilimumab and nivolumab) can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive the combination to see if it is safer and still eff…
Matched conditions: PATHOLOGIC STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
New drug cocktail shows promise against deadly brain metastases in melanoma patients
Disease control OngoingThis study tests whether combining two or three drugs can shrink or control melanoma that has spread to the brain. About 29 adults with untreated brain metastases will receive bevacizumab and atezolizumab, with or without cobimetinib. The goal is to see if these combinations are …
Matched conditions: PATHOLOGIC STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 11, 2026 12:10 UTC
-
New hope for kidney transplant patients with cancer: drug combo aims to fight tumors without losing the donated kidney
Disease control OngoingThis early-stage study tests whether a mix of three drugs—tacrolimus, nivolumab, and ipilimumab—can shrink or control certain skin cancers in people who have had a kidney transplant. The main goal is to see if the cancer responds without causing the body to reject the transplante…
Matched conditions: PATHOLOGIC STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 01, 2026 18:04 UTC
-
Fiber fix: diet study hopes to boost cancer immunotherapy
Knowledge-focused OngoingThis study looks at whether eating a high-fiber diet can change the gut bacteria of people with advanced melanoma who are receiving standard immunotherapy. About 50 participants will be randomly assigned to either a high-fiber or a healthy control diet for a set period. The main …
Matched conditions: PATHOLOGIC STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 12, 2026 12:07 UTC